TMCnet News
Global Graft Versus Host Disease (GVHD) Pipeline Review 2016 - Therapeutics Analysis of 60 Companies & 83 Drug Profiles - Research and MarketsResearch and Markets has announced the addition of the "Graft Versus Host Disease (GVHD) - Pipeline Review, H2 2016" report to their offering. 'Graft Versus Host Disease (GVHD) - Pipeline Review, H2 2016' outlays comprehensive information on the therapeutics under development for Graft Versus Host Disease (GVHD), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies Universities. 'Graft Versus Host Disease (GVHD) - Pipeline Review, H2 2016'; Graft Versus Host Disease (GVHD) pipeline therapeutics constitutes close to 99 molecules. Out of which approximately 83 molecules are developed by Companies and remaining by the Universities/Institutes. Graft Versus Host Disease (GVHD) Graft-versus-host disease (GVHD) is a complication that can occur after a stem cell or bone marrow transplant in which the newly transplanted donor cells attack the transplant recipient's body. Symptoms include abdominal pain or cramps, nausea, vomiting, and diarrhea, dry or irritated eyes, jaundice, shortness of breath, vaginal dryness and weight loss. Treatment includes immunosuppressants. It also reviews of key players involved in therapeutic development for Graft Versus Host Disease (GVHD) and features dormant and discontinued projects. Currently, The molecules developed by Companies in Phase III Phase II, Phase I, Preclinical, Discovery and Unknown stages are 6, 23, 14, 33, 5 and 2 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 3, 2, 10 and 1 molecules, respectively. Key Topics Covered:
For more information about this report visit http://www.researchandmarkets.com/research/ndzrfw/graft_versus_host
View source version on businesswire.com: http://www.businesswire.com/news/home/20161021005455/en/ |
